Preferred Label : Anti-PD-L1/4-1BB Bispecific Antibody QLF31907;
NCIt synonyms : Anti-PD-L1/CD137 Bispecific Antibody QLF31907; PD-L1 x 4-1BB Bispecific Antibody QLF31907; Anti-PD-L1/Anti-4-1BB Bispecific Antibody QLF31907;
NCIt definition : A bispecific antibody targeting the immunosuppressive ligand programmed death-1 ligand
1 (PD-L1; cluster of differentiation 274; CD274) and 4-1BB (CD137; tumor necrosis
factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory,
immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/4-1BB
bispecific antibody QLF31907 simultaneously targets and binds to 4-1BB, which is expressed
on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed
on tumor cells. Upon 4-1BB binding, QLF31907 acts as a conditional 4-1BB agonist in
the tumor microenvironment (TME), resulting in T-cell co-stimulation and enhances
T-lymphocyte-mediated anti-tumor activity. At the same time, QLF31907 prevents PD-L1
from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1;
CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific
T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead
to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits
the expansion and survival of CD8-positive T-cells, suppresses the immune system and
results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor
receptor superfamily, is an inducible costimulatory receptor that plays a key role
in T-cell proliferation, survival and cytolytic activity.;
Molecule name : QLF-31907; QLF 31907;
NCI Metathesaurus CUI : CL1907467;
Origin ID : C200459;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
